Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 42 (10), 899-907

Effect of Sarpogrelate and High-Dose Statin on the Reduction of Coronary Spasm in Vasospastic Angina: A Two by Two Factorial, Pilot Randomized Study

Affiliations

Effect of Sarpogrelate and High-Dose Statin on the Reduction of Coronary Spasm in Vasospastic Angina: A Two by Two Factorial, Pilot Randomized Study

So Ree Kim et al. Clin Cardiol.

Abstract

Background: Vasospastic angina (VSA) is characterized by coronary spasm, which can be aggravated by vasoactive substances such as serotonin. Hypothesis Sarpogrelate, a selective serotonin receptor antagonist, and high-dose statin have some effects on the reduction of coronary spasm in patients with VSA.

Methods: We recruited 100 patients with angiographically confirmed VSA, and randomly assigned them into four groups: sarpogrelate with high-dose statin (Group A, n = 25), sarpogrelate with low-dose or no statin (Group B, n = 25), placebo with high-dose statin (Group C, n = 25), and placebo with low-dose or no statin (Group D, n = 25). The primary endpoint was the remission of coronary spasm on 1-year follow-up provocation test.

Results: The most common site of coronary spasm was left anterior descending artery (42%). Most patients (96%) took calcium channel blockers, and 46% were treated with vasodilators. Overall, 40% of patients reported no chest pain at 1 year, and 23% showed complete remission of coronary spasm on 1-year follow-up provocation test. No difference was observed in symptomatic and angiographically complete remission rate between the sarpogrelate and the placebo group. Although the apolipoprotein B level at the 1-year follow-up was significantly lower in the high-dose statin group, symptomatic and angiographic outcomes were not different according to statin intensity. Distal thrombolysis in myocardial infarction (TIMI) flow on initial provocation test was independently associated with angiographically complete remission.

Conclusions: Sarpogrelate or high-dose statin did not significantly improve the angiographic remission rate in patients with VSA. Distal TIMI flow on initial provocation test could predict the complete remission of coronary spasm at follow-up.

Keywords: coronary spasm; high-dose statin; remission; sarpogrelate; vasospastic angina.

Conflict of interest statement

The authors declare no potential conflict of interests.

Figures

Figure 1
Figure 1
Trends of lipid profile. Curves denote trends of lipid profile in each group over 12 months of follow‐up. Group A, sarpogrelate with high‐dose statin group; Group B, sarpogrelate with low‐dose or no statin group; Group C, placebo with high‐dose statin group; Group D, placebo with low‐dose or no statin group. Abbreviations: HDL, high‐density lipoprotein; LDL, low‐density lipoprotein

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124:1774‐1782. - PubMed
    1. Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update. Circulation. 2009;119:2531‐2534. - PubMed
    1. Beltrame JF, Crea F, Kaski JC, et al. The who, what, why, when, how and where of vasospastic angina. Circ J. 2016;80:289‐298. - PubMed
    1. Yasue H, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary artery spasm‐‐clinical features, diagnosis, pathogenesis, and treatment. J Cardiol. 2008;51:2‐17. - PubMed
    1. Yasue H, Kugiyama K. Coronary spasm: clinical features and pathogenesis. Intern Med. 1997;36:760‐765. - PubMed

Grant support

LinkOut - more resources

Feedback